Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798751 | 0.98 | EPHX2 (0.60) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL19798752 | 0.95 | EPHX2 (0.60) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL19798753 | 0.92 | EPHX2 (0.64) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL20724718 | 0.84 | EPHX2 (0.55) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL2047350 | 0.79 | HSD11B1 (0.53) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL19798424 | 0.77 | KMT2A (0.58) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL7776473 | 0.76 | EPHX1 (0.73) | EPHX2EPHX1NPC1 | |
| SCHEMBL5860133 | 0.76 | EPHX1 (0.73) | EPHX2EPHX1NPC1 | |
| SCHEMBL653169 | 0.76 | EPHX1 (1.00) | EPHX2EPHX1NPC1KMT2AHSD11B1 | |
| SCHEMBL4565330 | 0.76 | EPHX2 (0.64) | EPHX2EPHX1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | EPHX2 1124/4885EPHX1 1923/4885NPC1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.